Prof Ali Bazarbachi speaks to ecancer about the real-world evidence on the use of antibody-drug conjugates in peripheral T-cell lymphoma.

Initially, he discusses the recent studies and the real-world evidence regarding the use of antibody-drug conjugates in peripheral T-cell lymphoma.

He further explains the results from ECHELON-2; 5-Year results of a randomised, double-blind, phase 3 study of frontline brentuximab vedotin + CHP VS CHOP in patients with CD30-positive peripheral T-cell lymphoma and what it means for the future of PTCL.

In the end, he mentions a few other studies presented in the last few years of significance regarding the use of ADCs for PTCL.
 

This programme has been supported by an unrestricted educational grant from Takeda.